Riskpilot← Back to searchSign inGet full accessJP Sälj & Konsult AB
ABActiveOrg 5569448490Krokforsvägen 11Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20131 employees
Revenue 2025
SEK 2,5M
+10% vs 2024
EBITDA margin
22.0%
+179% vs 2024
Equity ratio
69.5%
Financial strength
Net profit 2025
SEK 780K
+227% vs 2024
| Revenue | SEK 2,5M | +10% |
| EBITDA | SEK 543K | +179% |
| Net profit | SEK 780K | +227% |
| Total assets | SEK 4,9M | +15% |
| Equity | SEK 3,4M | +17% |
| Employees | 1 | — |
Legal name
JP Sälj & Konsult AB
Org number
5569448490
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
9 oktober 2013
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-09-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva försäljning av produkter, tjänster och hjälpmedel inom hälsa och friskvård, handel med värdepapper samt annan därmed förenlig verksamhet.
Address
Krokforsvägen 11
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 381 | 3 464 | 3 636 | 2 235 | 2 463 |
| Staff expenses | — | — | — | −984 | −1 020 |
| EBITDA | 848 | 1 541 | 1 455 | 195 | 543 |
| Depreciation & amort. | −0 | −0 | −2 | −7 | −7 |
| EBIT | 848 | 1 541 | 1 453 | 188 | 536 |
| Net financials | 264 | 62 | 358 | 56 | 403 |
| Profit before tax | 826 | 1 306 | 1 403 | 389 | 939 |
| Tax | −183 | −291 | −252 | −150 | −159 |
| Net profit | 643 | 1 015 | 1 151 | 239 | 780 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 360 | 3 508 | 4 788 | 4 238 | 4 856 |
| Equity | 1 388 | 2 103 | 2 954 | 2 893 | 3 373 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 379 | 515 | 536 | 191 | 330 |
| Total debt | 379 | 515 | 536 | 191 | 330 |
EBITDA margin
22.0%
This company
15.8%
Market median
+39% vs market
20212025
Equity ratio
69.5%
This company
38.2%
Market median
+82% vs market
20212025
Return on equity
23.1%
This company
18.4%
Market median
+26% vs market
20212025
Net profit margin
31.7%
This company
8.1%
Market median
+291% vs market
20212025
Asset turnover
0.51×
This company
1.12×
Market median
-54% vs market
20212025
Debt / equity
0.44×
This company
0.62×
Market median
+29% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-10-01 – 2021-09-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JF Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of JP Sälj & Konsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jonas Fredrik Pettersson | Chief Executive Officer | 0 companies |
| Jessika Maria Johansson | Deputy Board Member | 0 companies |